[6][7] Oxycyte is a perfluorocarbon (PFC) product composed of submicron particles of perfluoro(t-butylcyclohexane) in a 60% w/v concentration with an egg phospholipid emulsifier.

[1] Oxycyte was invented by Leland Clark and developed by Tenex Therapeutics, formerly Oxygen Biotherapeutics, Inc. and Synthetic Blood International.

Aurum Biosciences promoted Oxycyte as having potential use in multiple indications, including cardiology, oncology, and treating epilepsy and neurodegenerative diseases.

[14] Aurum Biosciences received a Wellcome Trust HICF funding to conduct a Phase I clinical trial with Oxycyte in stroke patients.

[15][16][17] In September 2014, Oxygen Biotherapeutics announced the discontinuation of a Phase IIB trial for its Oxycyte drug candidate, citing "difficulties enrolling patients".